BioPortfolio - Allos Therapeutics Incorporated
Allos Therapeutics Incorporated - Entry on Bioportfolio's Biocorporate Database.
http://www.bioportfolio.com/biocorporate/564-Allos_Therapeut...
|
Allos Therapeutics, Inc. Initiates Study of RH1 in Patients with ...
"We are pleased to advance the development of this agent," said Pablo J. Cagnoni , M.D., Chief Medical Officer of Allos. "RH1 is a small molecule ...
http://www.biospace.com/news_story.aspx?NewsEntityId=77283...
|
Allos Therapeutics Announces Presentations on EFAPROXYN(TM) and ...
Copies of the posters will be available on the Company's website, http://www. allos.com, the day following each presentation and will be archived for 30 days
...
http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=...
|
Allos Therapeutics, Inc. Scraps Brain Cancer Drug After Trial ...
19 Jun 2007 ... The web cast will be available from the homepage and the investors/media section of the Company's web site at http://www.allos.com and will ...
http://www.biospace.com/news_story.aspx?NewsEntityId=60435...
|
Allos Therapeutics to Present at the Rodman & Renshaw 10th Annual ...
Allos Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference. - WESTMINSTER, Colo.--(BUSINESS WIRE)--Allos Therapeutics, ...
http://biz.yahoo.com/bw/081104/20081104005203.html?.v=1...
|
Allos Therapeutics, Inc. to Continue Phase 2 Cancer Drug Study ...
The DMC is comprised of independent medical experts and was established by Allos as part of the Company's compliance with good clinical practice guidelines. ...
http://www.biospace.com/news_story.aspx?NewsEntityId=81379...
|
...
|
Allos Therapeutics, Inc. Release: PDX Shows Promising Activity In ...
12 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. today announced the presentation of interim results from an ongoing Phase 1/2 trial of PDX ...
http://www.biospace.com/news_story.aspx?NewsEntityId=4630...
|
Scheduled Combination of Allos Therapeutics' Pralatrexate Plus ...
Scheduled Combination of Allos Therapeutics' Pralatrexate Plus Gemcitabine Proves Superior to Methotrexate Plus Cytarabine in Models of Human Non-Hodgkin's
...
http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=...
|
Allos Therapeutics, Inc. Initiates Pivotal Phase 2 Study Of PDX In ...
29 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. today announced enrollment of the first patient in PROPEL, a pivotal multi-center Phase 2 study of the ...
http://www.biospace.com/news_story.aspx?NewsEntityId=28531...
|
